Candel Therapeutics
Manufacturing · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
117 Kendrick St Ste 450, Needham, Massac...Phone Number
(617) 916-5445Website
www.candeltx.comRevenue
-Stock Symbol
CADLIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
1
1
1
1
1
About Candel Therapeutics
Candel Therapeutics is developing viral immunotherapies that are designed to cause in situ vaccination against the unique antigens and neoantigens presented when tumor cells lyse and stimulate activation of both innate and adaptive immune mechanisms. The patient and tumor-specific memory response has been shown to produce a systemic and sustained anti-cancer effect based on a highly individualized T cell response against the injected tumor and uninjected metastases, and has the potential to change disease outcomes across a variety of indications.Explore more
Candel Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Candel Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Candel Therapeutics recently announced quarterly report
Candel Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Candel Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Candel Therapeutics
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Candel Therapeutics launches new products
Click to see if Candel Therapeutics had a recent Job posting/layoffs
Check out if Candel Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once Candel Therapeutics has new funding data
Recommended Actions
Find VP level buyers at Candel Therapeutics
Find 2 more new buyers
Compare Similar Companies to Candel Therapeutics
Compare insights from companies similar to Candel Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$123.9M
51-200
Public
$462.1M
1994
TC
Tracy ClementeChief People Officer & Chief Human Resources Officer
Company Profile Activity
Activity Insights
Candel Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Candel Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Candel Therapeutics.
Candel Therapeutics financials insights
Gather financial insights about Candel Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$14.2M
2019
Series B
$28.7M
Series C
$22.5M
2025
Debt
$130M
Candel Therapeutics Tech Stack
A closer look at the technologies used by Candel Therapeutics
See more technologies
Most Recent Scoops
Person-Based
Business Development, Finance, Investor Relations
New Hire
Executive Move
Executive Moves, New Hire
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Candel Therapeutics has reported that aglatimagene demonstrated a favorable safety profile in its Phase III prostate cancer trial, with flu-like symptoms observed in approximately one-third of patients typically mild and lasting one to two days and no increase in serious adverse events compared to placebo.
Project
Candel Therapeutics News & Media
Candel Therapeutics (CADL) CTO sells 7000 shares in planned trade - Stock Titan
Candel Therapeutics CTO Tyagarajan Seshu sold 7,000 shares at a $10.0216 average price under a Rule 10b5-1 plan, retaining 83,865 shares afterward.Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEEDHAM, Mass., July 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on June 30, 2026, the Compensation Committee of Candel’s Board of Directors (the Board) granted to one new employee, stock options to purchase an aggregate of 25,000 shares of the Company’s common stock, with a per shCandel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
NEEDHAM, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the initiation of the global pivotal phase 3 AURORA trial (NCT07660094), evaluating aglatimagene besadenovec (aglatimagene or CAN-2409) plus valacyclovir in combination with continued pembrolizumab in patients with metastaCandel Therapeutics Appoints Mark Sims as Chief Commercial Officer
NEEDHAM, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the appointment of Mark Sims as the Company’s Chief Commercial Officer, effective July 6, 2026. Mr. Sims will lead Candel’s commercial strategy and launch readiness for aglatimagene besadenovec (aglatimagene or CAN-2409) i
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Candel Therapeutics
Sign Up For FreeTo access detailed company insights
Candel Therapeutics is developing viral immunotherapies that are designed to cause in situ vaccination against the unique antigens and neoantigens presented when tumor cells lyse and stimulate activation of both innate and adaptive immune mechanisms. The patient and tumor-specific memory response has been shown to produce a systemic and sustained a... Read More
